Merck KGaA Said to Weigh Selling its Allergy Therapy Unit

Updated on
  • Merck may fetch about 600 million euros from business sale
  • Sale could attract strategic bidders and buyout firms

Merck KGaA is considering a sale of its allergy business as the German company seeks to reduce debt following the $17 billion takeover of Sigma-Aldrich Corp., according to people with knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.